ArticleFrontiers in oncology2025
Anlotinib induced type 1 diabetes: a case report.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Studies have shown some tyrosine kinase inhibitors (TKIs) can influence glucose metabolism leading to either hypoglycemia or hyperglycemia which is reversable in most patients after treatment cessation. Anlotinib is a novel oral multi-target tyrosine kinase inhibitor (TKI) which has been approved for non-small cell lung cancer in China. Previous studies of anlotinib did not report it has any side effect on blood glucose, and there has been no case reporting type 1 diabetes associated with any TKI. The present case study, to our knowledge, was the first to report on an 81-year-old man with lung cancer who developed type 1 diabetes following 14 cycles treatment with TKI. The fasting plasma blood glucose and hemoglobinA1c (HbA1c) was 24.3mmol/L and 9.0%, respectively, and GADA (glutamic acid decarboxylase antibody) was more than 2000IU/ml (normal range is less than 10IU/ml) when he was diagnosed. We also conducted a literature review to explore the potential mechanism of anlotinib in inducing type 1 diabetes and recommend that self-monitoring blood glucose (SMBG) for fasting and random postprandial blood glucose at least once a week is needed for early identification of glucose dysregulation when using TKI drugs, and monthly fasting and random postprandial plasma glucose monitoring and HbA1c test every 3 months is also recommended if the SMBG protocol cannot be completed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.